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Abstract 
Background: Copy number variants (CNVs) are established risk factors for 
neurodevelopmental disorders (NDD). To date the study of CNVs in psychiatric illness has 
focused on single disorder populations. The role of CNVs in individuals with intellectual 
disabilities (ID) and psychiatric co-morbidities are less well characterised. 
Aims: To determine the type and frequency of CNVs in adults with ID and co-morbid 
psychiatric disorders. 
Method: Chromosomal microarray analysis of 599 adults recruited from ID psychiatry 
services at three European sites. 
Results: The yield of pathogenic CNVs was high – 13%. Focusing on established NDD risk 
loci we find a significantly higher frequency in ID and co-morbid psychiatric disorder 
(10%), compared with healthy controls (1.2%, p<0.0001) schizophrenia (3.1%, p<0.0001) 
and ID/autism spectrum disorder (6.5%, p<0.00084) populations. 
Conclusions: In the largest sample of adults with ID and co-morbid psychiatric disorders to 
date, we find a high rate of pathogenic CNVs. This has clinical implications for the use of 
genetic investigations in ID psychiatry. 
Declaration of interest: None. 
  
Introduction 
Neurodevelopmental disorders (NDDs) are a group of disorders that are characterised by 
perturbed neurodevelopment — intellectual disabilities (ID), autism spectrum disorders 
(ASD) and schizophrenia are all considered to be NDDs (1). A proportion of the risk for 
NDDs can be attributed to a class of genetic variants known as copy number variants 
(CNVs) (2). A CNV is typically defined as a segment of DNA >1 kilobase, which is present at 
a higher (duplication) or lower (deletion) copy number as compared to a reference genome 
(3). ID has its onset in childhood and initially manifests with failure to meet developmental 
milestones, known as developmental delay (DD). In adulthood, a clinical diagnosis of ID is 
typically given when there are both deficits in adaptive and intellectual functioning (IQ 
score <70). ID can occur in isolation or in combination with a range of somatic, psychiatric 
and behavioural disorders. Association studies have shown the involvement of CNVs in 
psychiatric risk, in particular CNVs have been strongly implicated in the aetiology of 
schizophrenia (4) and ASD (5). Furthermore, investigations in large paediatric cohorts have 
revealed CNV regions that are significantly associated with ID (6). Many of these CNVs 
operate across traditional diagnostic boundaries: for example, 11 of the CNVs associated 
with ID are also risk factors for schizophrenia (7). The NDD risk CNVs that have been 
identified to date confer moderate to large risk (Odds Ratio 1.5 — ≥50)(7), and therefore 
have important clinical implications for affected individuals and at risk family members. 
A major challenge in the clinical interpretation of CNVs is the variable penetrance and 
expressivity of many NDD risk CNVs. For example not all individuals with a particular CNV 
display a neurodevelopmental phenotype (penetrance) and not all individuals express a 
severe phenotype (expressivity) (8). A large proportion — approximately 50% — of adult 
ID is idiopathic or of unknown cause (9). Chromosomal microarray analysis (CMA), the 
group of tests used to detect CNVs, have been one of the recommended first-tier test for 
clinical investigation of idiopathic ID since around 2010 and have primarily been 
undertaken in paediatric populations (10). Testing of adults with ID is particularly 
important for elucidating the relationship between rare CNVs and late-onset medical and 
psychiatric phenotypes. Indeed, the highest burden of pathogenic CNVs may be present in 
adults expressing co-morbid neurodevelopmental phenotypes. 
Method 
To the best of our knowledge, this study is the first multi-population analysis of CNVs in 
adults with ID and psychiatric co-morbidities and represents the largest sample of its kind 
to date. We aimed to determine; (i) the frequency of known NDD risk CNVs as compared to 
large population cohorts from the literature (healthy controls, ID/ASD and schizophrenia) 
(7); (ii) the overall rate of pathogenic CNVs; (iii) the relationship between pathogenic CNVs, 
level of ID and co-morbid psychiatric diagnoses; and (iv) likely pathogenic CNVs affecting 
neurodevelopmental candidate genes. 
Participant recruitment 
The GENMID (GENetics of Mental disorders in Intellectual Disability) consortium is 
comprised of three primary research groups based in Catalonia, Spain; Leuven, Belgium; 
and England, United Kingdom. In Catalonia participants were identified between 2009 — 
2012 from the Mental Health ID regional community Service Parc Hospitalari Martí i Julià, 
Girona. In Leuven, participants were recruited between 2005 — 2015 at the regional 
inpatient psychiatric unit for adults with ID in the St-Camillus Psychiatric Hospital, 
Bierbeek. Initially, only patients diagnosed with psychosis were recruited, but recruitment 
was later extended to other psychiatric phenotypes. In England, participants were 
recruited by consultant psychiatrists in intellectual disabilities between 2012 — 2015 from 
ID psychiatry caseloads at 32 National Health Service (NHS) trusts and 1 non-NHS 
provider. Written informed consent was obtained for all participants with capacity to 
consent and consultee/guardian advice was sought in absence of this. 
Recruitment criteria 
All sites recruited adults over the age of 18 years. Participants had idiopathic ID, defined as 
no clear genetic or environmental cause of ID as detailed in their medical records. 
Participants had one or more co-morbid psychiatric diagnoses and/or significant 
challenging behaviours. 
Phenotypic assessments 
For all sites the ID levels are in accordance with the ICD-10 ranges (<20 profound ID, 20—
34 severe ID, 35—49 moderate ID, 50—69 mild ID, 70—84 borderline ID). For further 
analyses, the <20—49 ranges were collapsed into a severe category and the 50—84 ranges 
were collapsed into a mild category. All sites identified psychiatric diagnoses from medical 
records and/or informants. Psychiatric diagnoses were converted from Diagnostic and 
Statistical Manual of Mental Disorders IV to ICD-10 criteria (with agreement between two 
psychiatrists). 
Genetic analysis and CNV Calling 
DNA was extracted from blood and saliva samples. Samples from Catalonia were analysed 
using the 400K Agilent platform (Agilent Technologies, Santa Clara, California, USA) at the 
Genetics Laboratory, UDIAT-Centre Diagnòstic, Parc Taulí Hospital Universitari. Samples 
from Leuven were analysed on the CytoSure ISCA oligoarray set (OGT, Oxford, UK) at the 
Constitutional Cytogenetics Unit of the Center of Human Genetics. Samples from England 
were analysed on the NimbleGen 135K platform (87%) (Roche NimbleGen, Madison, 
Wisconsin, USA) and the Cytoscan 750K platform (13%) (Affymetrics, Santa Clara, 
California, USA) at the North East Thames Regional Genetics Service Laboratory. 
CNV calling took place at the respective clinical laboratories, in keeping with internal 
laboratory protocols based on the American College of Medical Genetics best guidelines 
(11) or the Association of Clinical Genetic Science Best Practice Guidelines (12). 
CNVs reported by the clinical laboratories were classified into three categories: pathogenic, 
uncertain clinical significance and benign. The genome coordinates for all sites are 
reported according to the National Center for Biotechnology Information (NCBI) human 
genome build 37 (hg19, February 2009). All pathogenic CNVs were fed back to the 
participants' treating psychiatrist. 
Analysis methodology 
We aimed to compare the rates of known rare NDD risk CNVs in our cohort to rates in 
ID/ASD and schizophrenia cohorts. We used a list of 63 NDD risk CNVs that were 
associated with ID (6) and or schizophrenia from Rees et al. (7), henceforth referred to as 
NDD CNVs. NDD CNV carriers were identified using the criteria outlined in Kendall et al. 
(13), also used by Rees et al. (7), (personal communication), see supplementary table 1. 
CNVs fulfilling these calling criteria were classified as pathogenic and are included in the 
diagnostic yield. Duplications or deletions of the same chromosomal region were counted 
as separate loci (e.g. 22q11.2 del and dup). A rate percentage was calculated to enable 
comparisons between different sample sizes and chi-square tests were used to determine 
the population differences. The significance level has been adjusted to p=0.01 to account 
for multiple pairwise comparisons. 
To determine the CMA yield each individual was grouped by the most pathogenic CNV 
detected. Between site discrepancies were reclassified in accordance with Kearney et al. 
(11), see supplementary table 2. CNVs designated as of uncertain clinical significance were 
reclassified into likely benign or likely pathogenic using this methodology. We examined all 
likely pathogenic CNVs for recurrence and describe the main loci that have been implicated 
as NDD risk factors in the current literature. 
Finally, we performed chi-square tests (or Fisher's exact were there were five or less 
individuals) to examine the differences between psychiatric diagnoses, ID level and CNV 
pathogenicity. Since many of the co-morbid diagnoses are correlated and thus are non-
independent, correction of p-values through Bonferroni or other methods was deemed too 
stringent. Thus, we present all p-values uncorrected for multiple testing as recommended 
by several authors (14,15), while indicating the number of tests performed if all 
comparisons are not presented. All analyses were performed using R version 3.3.1 (16). 
  
Results 
We recruited 599 adults (Catalonia (n=80), Leuven (n=272) and England (n=247)) with ID 
and one or more co-morbid psychiatric diagnoses/challenging behaviours (376 (62.8%) 
male, mean age 43.2). Just more than half of the sample (50.8%) had severe ID and the 
remainder had mild ID. Each participant had on average 1.6 co-morbid psychiatric 
diagnoses, with pervasive developmental disorders being the most frequent diagnosis 
(25%), followed by unspecified non-organic psychosis (20%) (table 1 and supplementary 
table 3). The average number of CNVs per participant was 12.5 (7.4 deletions and 5.5 
duplications). Analysis of mean CNV size revealed that pathogenic CNVs were the largest 
followed by likely pathogenic, and both categories were significantly larger than likely 
benign and benign CNVs (supplementary figure 1). In line with guidelines of CNV 
categorisation our results follow the expected size distribution in that pathogenic CNVs are 
the largest. 
Table 1: Descriptive summary of GENMID cohort. 
 
GENMID 
Demographics  
N 599 
Ratio (Male/Female) 1.7 (376/223) 
Mean age (std.dev) 43.2 (14.1) 
ID Level  
Mild 49.2% 
Severe 50.8% 
Psychiatric diagnoses  
Average number of co-morbid diagnoses (range) 1.6 (1-5) 
F84 Pervasive developmental disorders 148 (25%) 
F29 Unspecified nonorganic psychosis 121 (20%) 
F61 Mixed and other personality disorders 108 (18%) 
Challenging behaviours 95 (16%) 
F32 Depressive episode 86 (14%) 
F41 Other anxiety disorders 60 (10%) 
F20 Schizophrenia 49 (8%) 
F31 Bipolar affective disorder 47 (8%) 
F90 Hyperkinetic disorders 41 (7%) 
F42 Obsessive-compulsive disorder 37 (6%) 
F43 Reaction to severe stress and adjustment disorders 27 (5%) 
F39 Unspecified mood disorder 25 (4%) 
 
Neurodevelopmental CNV frequency analysis 
In our sample, we found CNVs in 23 of the 63 NDD loci described by Rees et al. (7). At these 
23 loci we identified 58 CNV carriers, with two subjects carrying two risk CNVs. The rate 
percentage in our sample (rate of participants with a NDD CNV) is 10.0%, while the rate 
percentage is 6.5% in ID/ASD, 3.1% in schizophrenia and 1.2% in healthy control 
populations (table 2). The NDD loci frequencies are most comparable with the ID/ASD 
population, a sample which consisted mainly of children with DD/ID and/or ASD (6,7). 
However, we still observe significantly higher proportions of NDD CNVs in our ID and co-
morbid psychiatric diagnosis sample, 3.5% higher (95% CI = 1—6, P = 0.00084). 
Table 2: Rate (%) of CNVs at 63 neurodevelopmental disorder (NDD) risk loci in GENMID 
compared with populations rates reported by Rees et al. 2016. Rate percentage differences, 
95% confidence intervals (CI) and p-values for rate comparisons are indicated. 
Sample Sample size Rate (%) of the 63 NDD-loci Rate (%) difference (95% CI) p-value 
Healthy control 26628 1.2 8.8 (6.3-11) 2.8e-72 
Schizophrenia 20403 3.1 7 (4.5-9.5) 9.7e-21 
ID/ASD 29085 6.5 3.5 (1-6) 8.4e-04 
GENMID 599 10.0 - - 
 Figure 1: NDD CNV frequencies in the GENMID sample compared to frequencies in healthy 
controls (N = 26628), ID/ASD (N = 29085) and schizophrenia (N = 20403) cohorts as reported 
by Rees et al. (7). Rates for deletions extend down from the central line and duplications 
extend upwards. 
The frequencies of the 23 NDD CNVs identified in this cohort are shown in figure 1. The 
carrier frequency at each loci was the highest in our sample of ID and co-morbid mental 
illness, with the exception of four loci for which we see comparable frequencies to the 
ID/ASD cohort. The five most frequent NDD CNVs in the GENMID cohort, in order of 
frequency, are: 22q11.2 del (N=7, 1.2%), 15q11.2 Prader—Willi syndrome/Angelman 
syndrome (PWS/AS) dup (N=6, 1%), 16p11.2 dup (N=5, 0.8%), 15q13.3 del (N=5, 0.8%) 
and 16p12.1 del (N=4, 0.7%). A description of all CNV loci and the carrier phenotypes can 
be found in supplementary table 5. 
Pathogenic CNV yield 
In the GENMID sample 78 participants (13.0%, 95% CI 10.5-16.0) had at least one 
pathogenic CNV, with similar yields found at all research sites (Catalonia: 13.8%, Leuven: 
14.0%, and England: 11.7%). Pathogenic CNVs comprised those identified at the NDD loci 
previously described and a further 25 CNVs reported as pathogenic by the clinical 
laboratory services, see supplementary table 6. The pathogenic CNVs were predominantly 
deletions (59.5%). We previously reported a rate of 11% pathogenic CNVs in a subset of 
202 of the 247 participants from the England sample (17). When these 202 individuals are 
removed from the combined sample the diagnostic yield is 13.9%, thus replicating the 
initial finding. 
ID level, psychiatric diagnoses and CNV pathogenicity 
We examined group differences between CNV pathogenicity, psychiatric diagnoses and 
level of ID. We observe some differences in the proportions of ID and psychiatric diagnoses 
between the CNV pathogenicity groups (pathogenic, likely pathogenic, likely benign and 
benign; supplementary figure 2). However, no simple unidirectional relationships were 
observed. Equally, minor differences in the severity of ID were found between CNV 
pathogenicity groups, but no overall unidirectional relationship was observed. 
Likely pathogenic CNVs 
The yield of likely pathogenic CNVs in the sample was 21.5% (95% CI 18.4-25.1). 
Investigation of recurrent likely pathogenic CNVs revealed 34 CNVs in 16 regions 
(supplementary table 4). Four recurrent CNVs identified here corroborate existing 
evidence for the involvement of these regions in neurodevelopmental risk (figure 2). 
 Figure 2: The locations of four overlapping likely pathogenic CNVs in the GENMID cohort that 
are implicated in neurodevelopmental disorders in the literature (UCSC genome browser). 
 
First, we identified two carriers of exonic duplications in the CNTN6 gene at 3p26.3. The 
CNTN proteins belong to an immunoglobulin super family of cell adhesion molecules and 
have an important role in neurodevelopmental processes (18). CNTN6 duplications were 
first identified in patients with ASD (19,20) and later in a patient with ID and facial 
dysmorphisms (21). A review of 14 patients with CNTN6 CNVs revealed that both CNV 
deletions and duplications affecting CNTN6 are thought to be involved in variable 
neuropsychiatric phenotypes (22). The participants identified in our study both presented 
with mild ID. One had schizophrenia and personality disorder, and one had challenging 
behaviours and had been convicted of a serious criminal offence. Interestingly, the 
participant with schizophrenia and personality disorder also had a duplication in the 
CNTN4 gene. CNVs affecting CNTN4 are also thought to confer risk for various NDDs (23). 
Second, we identified two participants with CNV duplications at the 9q21.32q21.33 locus 
encompassing the SLC28A3 and NTRK2 genes. SLC28A3 is a nucleoside transporter 
involved in the regulation of multiple processes, including neurotransmission; however, 
there are no prior reports of its role in psychiatric risk. NTRK2 is a receptor tyrosine kinase 
with numerous neurodevelopmental functions, including synapse formation and plasticity. 
Altered NTRK2 expression has been identified in the brains of patients with schizophrenia 
(24). One participant had severe ID and bipolar disorder (BPD), and the other had mild ID 
with unspecified non-organic psychosis. 
Third, we identified five participants with exonic CNVs in the CHD gene family. The CHD 
proteins are involved in chromatin structure remodeling and the epigenetic regulation of 
transcription. Three of the participants had exonic CNVs (2 duplications, 1 deletion) in the 
CHD8 gene at 14q11.2, which also encompass SUPT16H. The protein encoded by the 
SUPT16H gene is thought to be involved in DNA replication and repair. CNV deletions 
affecting CHD8 and SUPT16H were initially described in children with DD and dysmorphic 
features (25). Variants in the CHD8 gene are thought to confer a phenotypic subtype of ASD, 
comprising macrocephaly, facial dysmorphologies and gastrointestinal abnormalities (26). 
Both deletions (27) and duplications (28,29) affecting CHD8 and SUPT16H have been 
described with variable neurodevelopmental phenotypes. The two participants with CNV 
duplications both had severe ID, one was diagnosed with schizophrenia and the other with 
BPD. The participant with the CNV deletion also had severe ID and ASD. 
Last, we identified two participants with exonic CNVs in the CHD2 gene at 15q26.1 (one 
deletion and one duplication). Several patients have been described with CHD2 deletions; 
with a common phenotype of ID, epilepsy, and aggressive challenging behaviours (30,31). 
To our knowledge, a CNV duplication in CHD2 has not previously been described in the 
literature. The deletion carrier had severe ID and schizoaffective disorder, and the 
duplication carrier had challenging behaviours and BPD. Both patients also had an epilepsy 
phenotype. 
  
Discussion 
There is a paucity of research on CNVs in adults with ID and co-morbid psychiatric 
phenotypes. This poses a challenge for genetic counselling of novel and rare CNVs, as 
descriptions of later-life phenotypes are largely unavailable. Previous investigations in this 
patient group identified a diagnostic yield of 11% CNVs classed as clinically relevant (17). 
In this study, utilising data from three European research sites, we replicate this finding 
with a higher diagnostic yield of 13.0% pathogenic CNVs in 599 participants (or 13.9% 
with the previously reported cases removed). Given that CMA is being advocated for use in 
schizophrenia cohorts, in which the diagnostic yields are lower (between 2.5—5%) 
(32,33), adults with ID presenting to psychiatric services appear to be a group to prioritise 
for CMA. 
We found CNV carriers at 23 out of the 63 NDD loci. It is unsurprising that we didn't find 
carriers in the remaining 40 loci, as these CNVs are very rare with reported frequencies in 
ID between 0.01—0.26% (mean = 0.06%) (7). Presuming that there is an additive effect of 
having both ID and a co-morbid psychiatric disorder, then we would expect to see an 
increased frequency of the 63 NDD CNVs in our cohort. Indeed, the cumulative frequency 
was significantly higher, as compared to both ID/ASD populations not selected for 
psychiatric co-morbidity and individuals with schizophrenia. 
The phenotypic presentation of the NDD CNV carriers is highly variable, both in terms of 
the level of ID and the psychiatric diagnoses. This indicates a broader role for genes within 
these CNV loci in conferring general, as opposed to disorder specific, psychiatric risk. It is 
possible that this clinical heterogeneity partly reflects the difficulty of diagnosing 
psychiatric disorders in individuals with ID. Interestingly, at least one CNV carrier at each 
of the five most frequent loci has a psychosis phenotype. Of particular interest are the four 
carriers of the 16p12.1 deletion, which was significantly associated with risk for 
schizophrenia by Rees et al. (7). Three of the four carriers had a psychosis phenotype, 
offering further support for this locus as a risk factor for both ID and psychotic disorders. 
Second, we determined the diagnostic yield of CMA in our cohort. In addition to the CNVs 
identified at known NDD loci, we identified a further 25 CNVs that were reported as 
pathogenic by the clinical genetic services. The majority of these were large deletion CNVs 
(1.7Mb—13.2Mb), which overlapped CNVs described in single case reports in the existing 
literature. This group of CNVs are likely to be extremely rare and thus would not be 
observed at high enough frequencies in existing case—control studies. We were unable to 
identify any clear relationship between ID level, co-morbid psychiatric diagnoses and CNV 
pathogenicity level. This may indicate that NDD CNVs generally have pleiotropic effects, 
however research with larger sample sizes would be required to further investigate this. 
Last, we investigated likely pathogenic CNVs of uncertain clinical significance. Following a 
literature review of likely pathogenic CNVs that recur in our sample, we were able to offer 
further support for the involvement of particular CNV regions in neurodevelopmental and 
psychiatric risk. Unlike the pathogenic CNVs, many of the likely pathogenic CNVs were 
small (<1Mb) and affected only a small number of genes. There is a growing body of 
literature for the role of the CNTN and CHD gene families in risk for ID and co-morbid 
psychiatric disorders. Again, the phenotypes associated with CNVs affecting these genes 
appear to be highly variable. It is important to consider the clinical implications of these 
CNVs, which were not initially reported as pathogenic by the clinical genetics services. 
Our findings suggest that if CMA is to be offered more widely to adults with ID presenting 
with mental disorders many would receive a new genetic diagnosis. Such diagnoses have 
many implications. They provide, at least, a partial explanation for the person’s physical 
and mental health problems, which in turn may have an effect on illness related beliefs of 
patients, their families and healthcare professionals. For some CNVs medical and 
psychiatric associations across the life course are now well described, with implications for 
clinical management. For example, the 22q11.2 deletion has recommendations for physical 
health screening, include cardiac, renal and immunology investigations, and psychiatric 
screening (34). Whilst clinical recommendations for some pathogenic CNVs are less clear, it 
is important to note that 70% of the CNVs we identified were in NDD risk loci, for which 
there are existing scientific literature and/or clinical disorder guides available for families 
and clinicians (35). Identification of pathogenic CNVs also has broader implications for 
family members, including cascade testing, provision of recurrence risk information and 
access to support groups. Given the rapid progress of genomic medicine there is a need for 
research to address questions of clinical utility and adverse outcomes in order to optimise 
the process of genetic investigation in ID psychiatry. 
One of the limitations of this study is that there were some differences between the 
populations recruited at the different sites, for example participants were recruited from 
in-patient psychiatric services in Leuven and outpatient services in Catalonia and England. 
Most individuals lacked inheritance data, which is a valuable aid in categorisation of rare 
variants and may have led to an under estimate of our yield. Different platforms were 
utilised to detect the CNVs at the different sites; however, as all the platforms used were 
high resolution this is unlikely to have major effects. Finally, a true estimate of the 
association between CNV pathogenicity and NDD phenotypes would require much larger 
case-control samples or epidemiological based studies. 
This, to our knowledge, is the first large multi-population study of CNVs in idiopathic ID 
with co-morbid psychiatric disorders. We detected a 13% rate of undiagnosed pathogenic 
CNVs. From a research perspective, studying this population revealed the highest rate of 
CNVs at established NDD loci and recurrent likely pathogenic CNVs, both offering unique 
opportunities for further phenotyping of rare variants. Increased clinical testing and 
research in this population should be a priority for both clinicians and researchers in the 
field of psychiatric genetics. 
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